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Abstract
In prior investigation, we discovered that (3'R,4'R)-3-cyanomethyl-4-methyl-3',4'-di-O-(S)-
camphanoyl-(+)-cis-khellactone (4, 3-cyanomethyl-4-methyl-DCK) showed promising anti-HIV
activity. In these current studies, we developed and optimized successfully a practical ten-step
synthesis for scale-up preparation to increase the overall yield of 4 from 7.8% to 32%. Furthermore,
compound 4 exhibited broad-spectrum anti-HIV activity against wild-type and drug-resistant viral
infection of CD4+ T cell lines as well as peripheral blood mononuclear cells by both laboratory-
adapted and primary HIV-1 isolates with distinct subtypes and tropisms. Compound 4 was further
subjected to in vitro and in vivo pharmacokinetic studies. These studies indicated that 4 has moderate
cell permeability, moderate oral bioavailability and low systemic clearance. These results suggest
that 4 should be developed as a promising anti-HIV agent for development as a clinical trial candidate.
As of February 2008, thirty-two anti-HIV drugs have been licensed by the US Food and Drug
Administration (FDA) (http://www.fda.gov/oashi/aids/virals.html). These compounds include
eleven HIV protease inhibitors, seventeen nucleoside and nonnucleoside reverse transcriptase
(RT) inhibitors, one fusion inhibitor, one entry inhibitor (CCR5 co-receptor antagonist), one
integrase inhibitor, and one multi-class combination product. Clinical combinations of these
drugs, known as highly active antiretroviral therapy (HAART), have significantly reduced the
morbidity and mortality of AIDS. However, increasing numbers of HIV/AIDS patients on
HAART regimens fail to respond to current antiretroviral drugs due to the emergence of drug-
resistant HIV mutants.1 Therefore, it is essential to develop additional potent anti-HIV drugs
with novel mechanisms of action or resistance profiles different from those of current anti-HIV
therapeutics.
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In our prior studies, 3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (1, DCK, Figure 1) 2 and
its analogs were identified as a novel class of anti-HIV agents with potent activity in H9
lymphocytes. Systematic modification of 1 provided more than 150 khellactone derivatives,
including mono-, di-, and tri-substituted 1-analogs, and their SAR study results have been
published. 3, 4, 5, 6 Notably, mechanistic studies have demonstrated that 1 and its analogs do
target HIV-1 RT; however, they do not interfere with its RNA-polymerase activity, but instead
inhibit its DNA-dependent DNA polymerase activity. Thus, 1-analogs suppress the production
of double-stranded viral DNA from a single-stranded DNA intermediate,7 in stark contrast to
current HIV-1 RT inhibitors that block the generation of single-stranded DNA from a RNA
template. This unique mechanism of action provides an opportunity to discover a novel NNRTI
that remains effective against HIV-1 RT multi-drug resistant strains. Thus, we were strongly
prompted to develop additional potent 1-analogs as potential clinical trial candidates.
Due to its high potency and easy synthesis, 4-methyl-DCK (2) was chosen as the first drug
candidate for preclinical studies. However, the poor bioavailability of 2 has limited its further
development. Subsequently, another promising candidate 3-hydroxymethyl-4-methyl-DCK
(3, HMDCK) showed moderate bioavailabity, but lacked activity in a drug resistant strain.8
Guided by SAR and 3D-QSAR results,9 our research efforts next focused on the development
of drug candidates with better pharmacokinetic profiles and potent anti HIV-1 drug-resistant
activity. A cyano group shows good metabolic stability under most conditions. Moreover, it
is also a good H-bond acceptor and can favorably interact with Tyr or Ser amino-acid residues
on the NNRTI binding site surface, which are critical determinants for several NNRTIs
affinities.10 In addition, reported evidence suggests that by introducing a cyano group, such
as seen with the potent anti-HIV drug etravirine, the binding affinity of a quinazoline inhibitor
to its target (containing Tyr30 and Tyr50) increased dramatically by 30,000-fold, due to
hydrogen bond formation between the cyano nitrogen and two phenol hydroxyls of two
tyrosines.11 Based on the aforementioned evidence, the 3-cyanomethyl moiety was selected
to replace the 3-hydroxymethyl group of 3. As we expected, (3'R,4'R)-3-cyanomethyl-4-
methyl-DCK (4) discovered through this study not only exhibited promising potency against
wild-type HIV-1 replication in H-9 lymphocytes (Table 4),6 but also showed activity against
several resistant strains. In this paper, we report the broad-spectrum anti-HIV potency of 4
against wild-type and drug resistant viral stains, its pharmacokinetic, and a practical synthetic
protocol for scale-up synthesis of this promising compound.
Chemistry
As stated above, because 4 is a good potential drug candidate for preclinical studies, a practical
synthesis for scale-up of 4 is merited and has been developed. The total yield of 4 was
significantly increased from 7.8% in the original seven-step synthesis6 to 32% in the new ten-
step synthesis with optimized conditions, as shown in Scheme 1 and Table 1. The key
intermediate 3,4-dimethylseselin (11) was originally prepared from 3,4-dimethyl-7-
hydroxycoumarin (6) by a two-step reaction (see Scheme 1, steps a,b): a) nucleophilic
substitution with 3-chloro-3-methyl-1-butyne, followed by b) Claisen rearrangement and
cyclization in N,N-diethylaniline at reflux temperature (>200 °C). However, formation of a
linear pyranocoumarin isomer was unavoidable, resulting in lower yields and difficult
purification in scale-up synthesis. Thus, the following alternative synthetic route was
developed to synthesize intermediate 11 exclusively and efficiently. Acetylation of the 7-
hydroxyl of 6 with refluxing acetic anhydride provided 7-acetoxycoumarin 7 in 96% yield. By
using AlCl3 and slowly heating to 180 °C, 7 underwent Fries arrangement providing 8-acetyl-7-
hydroxycoumarin (8), which was easily purified by crystallization from EtOH, in an 83% yield.
Meanwhile, we separated the filtrate by column chromatography to obtain a small amount of
6-acetylated isomer. The structures of 8 and its 6-acetylated isomer were identified by
spectroscopic analysis, and HPLC showed that the crystalline 8 was pure, with no 6-acetylated
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isomer being detected. Condensation of 8 with acetone in the presence of pyrrolidine yielded
the fused angular pyranocoumarin 9 in an 81% yield. Reduction of the 4'-carbonyl of 9 with
NaBH4 in MeOH yielded 10. Without purification, subsequent dehydration of 10 with TsOH
exclusively generated key intermediate 3,4-dimethylseselin 11, which was readily purified by
crystallization from EtOH. This current five-step preparation of 11 from 6 has a total yield of
59%, which is much higher than the 38% yield obtained in the original two-step synthesis,
even though it is three steps longer. Additionally, this modified route to the key intermediate
11 has additional advantages for scale-up synthesis: it avoids production of the linear isomer,
does not require chromatographic purification, and eliminates use of the costly reagent 3-
chloro-3-methylbutyne-1 and the environmental contaminant N,N-diethylaniline.
Sharpless asymmetric dihydroxylation of 11 yielded (3'R,4'R)-3,4-dimethyl-(+)-cis-
khellactone, which was dried in vacuo and used directly, without further purification, in the
acylation step with (S)-camphanic chloride in pyridine and CH2Cl2. (3'R,4'R)-3,4-Dimethyl-
DCK (12) was produced in a two-step yield of ca. 77%, with less than 5% of the (3'S,4'S)-
isomer, as measured by HPLC. Compound 12 was treated with N-bromosuccinimide at a mole
ratio of 1:1.2 in refluxing benzene for 4 h to produce exclusively 3-bromomethyl-4-methyl-
DCK (13)4, 6 in 97% yield. Even though both 3- and 4-methyl groups were present,
bromination occurred regioselectively only at the 3-methyl. In addition to 1H NMR shifts, the
position of bromination was verified using NOE (Nuclear Overhauser Effect) measurement,
in which the signals of a methyl singlet (2.41 ppm, s) and 6-proton (6.80 ppm, d, J = 8.8 Hz)
showed obviously increased response of ca. 14% and 12%, respectively, when the 5-proton
(7.61 ppm, d, J = 8.8 Hz) was irradiated. This fact indicated that the 3-methyl has higher
reactivity than the 4-methyl during free–radical type bromination.
Another major improvement was the cyanation of 13. In our original synthesis, compound
13 was reacted with sodium cyanide in DMSO at 60 °C to give 4 in a 49% yield.6 However,
DMSO is an environmental contaminant and not a suitable solvent for scale-up synthesis of a
drug candidate, especially when used in the last step. Nitriles are generally prepared by reacting
primary alkyl halides with inorganic metal cyanide salts; thus, a suitable solvent system in
which both kinds of reagents are soluble is very crucial. We investigated the impact of various
solvents and phase-transfer catalysts as shown in Table 2 to find a better solvent system.
Accordingly, we tried first to use the polar aprotic solvent anhydrous DMF or acetonitrile rather
than DMSO (entries 1 and 2, respectively). After stirring at room temperature for 24 h, both
reactions failed because the inorganic sodium cyanide was barely soluble in these solvents.
Adding a small amount of water to the DMF (DMF/water 60:1 v/v) greatly increased the
solubility of sodium cyanide, resulting in a 75% yield of product (entry 3). However, the 1H
NMR spectrum of the product showed two different proton signals (δ 3.72 and 5.27 ppm) for
the 3-CH2 in a ratio of ca. 3.5:1, which indicated that the product was a pair of isomers. Each
isomeric product could be obtained exclusively by using two-phase CHCl3/H2O in the presence
of tetrabutylammonium iodide (Bu4N+I−) when the reaction was carried out at room
temperature (entry 4) or reflux (entry 5, 60–70 °C). The former conditions provided only one
product (3-CH2 signal at δ 3.72 ppm) and the latter conditions afforded the other product (3-
CH2 signal at δ 5.27 ppm) in 1H NMR spectrum. Additional spectroscopic evidence (13C NMR,
MS, and IR spectra) confirmed that the former product was the nitrile 4, and the latter compound
was the isonitrile isomer 4b. Their spectroscopic differences are shown in Table 3. Products
4 and 4b had HPLC retention times of 10.9 and 5.6 min, respectively.
Other phase-transfer catalysts, including benzyltriethylammonium chloride,
methyltriethylammonium chloride, dibenzo-18-crown-6, and cetyltrimethylammonium
chloride, were also investigated in the two-phase reaction system (data not shown), but
Bu4N+I− gave better results. Addition of Bu4N+I− directly into DMF (entry 6) or acetonitrile
(entry 7) improved the solubility of sodium cyanide and gave moderate yields of nitrile and
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isonitrile, respectively, compared with failed entries 1 and 2. Furthermore, the effects of other
polar aprotic or protic solvents with or without Bu4N+I− (entries 8–13) were investigated.
Different solvents afforded either nitrile 4 or isonitrile 4b exclusively. EtOH [containing water
or anhydrous, with or without Bu4N+I− (entries 10–13)] showed high yields of nitrile 4.
Because EtOH is safe and inexpensive, it is usually a good solvent choice for scale-up synthesis.
However, compound 13 had limited solubility in EtOH when the reaction scale was increased.
Thus, a mixed solvent system of 95% EtOH/DMF (3:2 v/v) (entry 14) was developed. Alkyl
bromide 13, which is soluble in DMF, was added slowly to an EtOH solution of sodium cyanide
over a 10–15 min period. After 2 h stirring at room temperature, this reaction produced only
the expected cyanide 4 in a 74% yield. The [α] value of pure 4 is +22.81° in chloroform, in
which 3'S,4'S stereoisomer of 4 was measured less than 0.5% by HPLC.
Results and Discussion
Broad-spectrum Anti-HIV Activity
In our previous studies, compound 4 exhibited similar potency to parent compounds 2 and 3,
but lower toxicity in HIV-1IIIB infected H9 lymphocytes assay (Table 4).4,6 In the current
study, we further tested compound 4 in other different assays, including laboratory-adapted,
primary isolates and drug-resistant strains (Table 5, Table 6 and Table 7). It should be noted
that, due to different protocols, the current assay is less sensitive. Further screening results
indicate that compound 4 exhibited potent inhibitory activity against infection of CD4+ T cell
lines and peripheral blood mononuclear cells (PBMCs) by laboratory-adapted and primary
HIV-1 isolates. The inhibitory activity of 4 on infection of CD4+ T cells and, MT-2 and MT-4
cells by laboratory-adapted HIV-1 strains IIIB and Lai (X4-tropic virus), and Bal (R5-tropic
virus) was determined as previously described.12,13 The in vitro cytotoxicity of 4 was assessed
using a XTT assay.14 As shown in Table 5 and Table 7, compound 4 significantly inhibited
infection by both X4- and R5-tropic viruses with EC50 values at sub-micromolar levels and
selective index (SI) values ranging from 66 to 182. Subsequently, we sought to determine
whether 4 is also effective against HIV-1 variants resistant to RTIs. As shown in Table 6,
compound 4 had an EC50 of approximately 4 µM, for inhibiting infection by HIV-1 7324-1,
which is a panel of fourteen prototypical infectious multidrug resistant HIV-1 reverse
transcriptase (RT) clones, including those with each of the published nucleoside analog RT
mutations in the combinations that occur most frequently in HIV-infected individuals.15 This
value is about eight-fold higher than that against infection by wild-type HIV-1 IIIB. This result
suggests that the multi-drug resistant HIV-1 variant is only moderately resistant to 4,
confirming that the newly synthesized 4 is an RTI with better resistance profiles than other
RTIs
CD4+ T lymphocytes in PBMCs are the primary target cells for HIV-1 infection. Based on the
HIV-1 envelope gene sequences, primary HIV-1 isolates can be classified into different
genotypes, i.e. Group M subtypes A – H and Group O.16, 17, 18 A, C, D and G subtypes
predominate in sub-Saharan Africa19, E subtype in Thailand,20 and B subtype in the United
States and Western Europe.21 HIV-1 isolates can be further classified into R5-, X4- and dual
(R5X4)-tropic viruses, which use CXCR4, CCR4 or both coreceptors, respectively.17, 22,
23 We tested the inhibitory activity of 4 on infection by a series of primary HIV-1 isolates. As
shown in Table 7, compound 4 significantly inhibited infection of PBMCs by all primary HIV-1
isolates tested, including subtypes A, B, C, D, G, and group O with R5- and X4R5 dual-
tropisms. The EC50 values for inhibition of HIV-1 infection in PBMCs ranged from 0.8 to 10
µM. These results suggest that 4 has potent antiviral activity against a broad-spectrum of HIV-1
isolates.
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To be a useful anti-HIV drug candidate, a compound must be able to penetrate the cell
membrane in order to interfere with replication steps inside the cell. In a colonic
adenocarcinoma cell (Caco-2) assay, 4 had an apparent permeability coefficient (Papp) of 5.16
× 10−6, indicating that it can readily penetrate the cell membrane.
In in vivo studies, compound 4 was administered via intravenous (i.v. 2 mg/kg) and oral (i.g.
suspension, 20 mg/kg) routes to adult male Sprague-Dawley rats (180–200 g). Nine blood
samples (0.4 mL) were collected sequentially over an 8-h period and immediately centrifuged.
The separated plasma samples were stored at −20 °C for analysis. Pharmacokinetic parameters
were calculated by non-compartmental analysis by using DAS Version 2.0. Initially,
compounds 3 and 4 were administered as carboxymethylcellulose (CMC) suspensions, and
although both compounds showed fairly low absorption in vivo, 4 was clearly better than 3
(Figure 2). To improve solubility and thus increase absorption in vivo, compound 4 was then
administered in 10% poly(ethyleneglycol) (PEG) 400 to rats via intravenous and oral routes.
Using this administration vehicle, 4 exhibited moderate oral bioavailability (F = 17.8%) in the
rat, as shown in Table 8 and Figure 3. Meanwhile, compound 4 also showed low systemic
clearance (0.052 L/min/kg) and a moderate half time (167 min). Thus, current results indicate
that the presence of the cyano moiety resulted in improved molecular pharmaceutical properties
and provided lower lipophilicity, low systemic clearances, additional absorption, and longer
half-life, subsequently enhancing oral bioavailability. Therefore, compound 4 should be further
developed as a potential drug candidate.
Conclusions
Drug-resistance has become a critical problem in the development of new NNRTIs. However,
further modification of 2 has led to the identification of 4 as a new promising lead for anti-HIV
preclinical studies. It possesses not only potent antiviral activity against infection of CD4+ T
cell lines and PBMCs by both laboratory-adapted and primary HIV-1 isolates with distinct
subtypes and tropisms, but also moderate efficacy against multi-drug resistant HIV strains. In
addition, a practical 10-step synthesis of 4 was successfully developed and optimized. In
particular, the preparation of the key intermediate 11 and the cyanation in the final step were
greatly improved. The modified synthesis gave a high overall yield of 32%, with minimized
isomer formation, simplified purification, and elimination of high-cost reagents and toxic
solvents, thus providing clear advantages for further scale-up synthesis. Pharmacokinetic
studies also indicated that 4 has moderate oral bioavailability and cell permeability, and a
reasonable half-life. All current results suggest that 4 has potential for development into an
anti-HIV clinical trials candidate.
Experimental Section
General Information
Melting points were measured on a RY-1 melting apparatus without correction. 1H NMR
spectra were measured on a JNM-ECA-400 spectrometer using TMS as the internal standard.
The solvent used was CDCl3 unless otherwise indicated. Mass spectra were measured on a
Perkin-Elmer Sciex API-3000 mass with Turbo Ionspray ionization. HPLC (Agilent 1100)
experimental conditions were as follows: C18 column (15 cm × 0.4), 60% acetonitrile plus 25
mM HOAc/H2O as mobile phase, 1.5 mL/min flow rate, UV detection at λ = 320 nm. The
diastereoisomeric excess percentages were measured by HPLC. Silica gel (GF245 and 200–
400 mesh) was purchased from Qingdao Haiyang Chemical Co., Ltd for TLC, PTLC, and
column chromatography. A Flash+ system from Biotage, Inc. was used for medium-pressure
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column chromatography. All other chemicals were obtained from Beijing Chemical Works or
Aldrich, Inc.
3,4-Dimethyl-7-hydroxycoumarin (6)
A mixture of resorcinol (5, 44.0 g, 0.4 mol) and ethyl 2-methylacetoacetate (66 mL) in a 1:1.15
molar ratio was quickly dropped into H2SO4 (98%, 120 mL) with vigorous stirring at ice-bath
temperature for 10–15 min. The mixture was stirred at room temperature for 2–3 h, poured
into ice-water, and allowed to stand overnight. The precipitated white solid was filtered, washed
with water until neutral, and dried in vacuo to produce 73.7 g of 6 (97% yield), colorless crystals
from EtOH, mp 220 °C dec; 1H NMR (CD3OD) δ 2.11 (3H, s, CH3-3), 2.38 (3H, s, CH3-4),
6.65 (1H, d, J = 2.4 Hz, H-8), 6.77 (1H, dd, J = 2.4 & 8.8 Hz, H-6), 7.57 (1H, d, J = 8.8 Hz,
H-5).
7-Acetoxy-3,4-dimethylcoumarin (7)
3,4-Dimethyl-7-hydroxycoumarin (6) (19.0 g, 100 mmol) in acetic anhydride (50 mL) was
heated to reflux for 1.5 h. After cooling to 50 °C, the reaction mixture was slowly poured into
ice-water (300 mL) with vigorous stirring. The solid was filtered, washed with water until
neutral, and recrystallized from 95% EtOH (500 mL) to yield 7 as light yellow needles 22.3 g,
96% yield, mp 164-5 °C; 1H NMR δ 2.21 (3H, s, 3-CH3), 2.34 (3H, s, 4-CH3), 2.39 (3H, s, 7-
CH3CO), 7.05 (1H, dd, J = 2.4 & 8.4 Hz, 6-H), 7.08 (1H, d, J = 2.4 Hz, 8-H), 7.60 (1H, d, J =
8.4 Hz, 5-H).
8-Acetyl-3,4-dimethyl-7-hydroxycoumarin (8)
7-Acetoxy-3,4-dimethylcoumarin (7) (23.2 g, 100 mmol) and anhydrous aluminum chloride
(53.4 g, 400 mmol) were mixed and ground to a fine powder. The mixture was placed in a flask
(500 mL) and heated from 130 °C to 180 °C (in an oil bath) within 2 h, and kept at 170–180 °
C for another 2 h. After scraped ice (120 g) was added to the flask at room temperature, 5%
aq HCl (300 mL) was slowly dropped into the flask with vigorous stirring. The mixture was
then heated slowly to 110 °C and kept at the same temperature for 1 h to produce a suspension.
The solid was filtered, washed until neutral, and then crystallized from EtOH (500 mL) to yield
8 (19.3g), 83% yield, yellow crystals, mp 175–176 °C; 1H NMR δ 2.21 (3H, s, 3-CH3), 2.39
(3H, s, 4-CH3), 2.97 (3H, s, 8-CH3CO), 6.91 (1H, d, J = 8.8 Hz, 6-H), 7.69 (1H, d, J = 8.8 Hz,
5-H), 13.46 (1H, s, 7-OH). A small amount of 6-acetyl-3,4-dimethyl-7-hydroxycoumarin, an
isomer of 8, was obtained via flash column chromatography from the crystallization filtrate,
mp 213–214 °C; 1H NMR δ 2.21 (3H, s, 3-CH3), 2.42 (3H, s, 4-CH3), 2.72 (3H, s, 6-CH3CO),
6.85 (1H, s, 8-H), 7.97 (1H, s, 5-H), 12.56 (1H, s, 7-OH).
3,4-Dimethyl-3'4'-dihydroseselin-4'-one (9)
A mixture of 8 (23.2 g, 100 mmol), pyrrolidine (2 mL), acetone (20 mL, excess) and
CH2Cl2 (100 mL) was stirred at room temperature for 48 h. The mixture was then poured into
ice-water (50 mL), acidified with 5% aq HCl to pH 5–6, and extracted with CH2Cl2 three times.
The organic phase was washed to neutral and dried over Na2SO4, and then the solvent was
removed in vacuo. The residue was re-crystallized from EtOH to produce 9 as light yellow
crystals: 25.8 g, 81% yield, mp 213-4 °C; 1H NMR (DMSO) δ 1.43 (6H, s, 2’-CH3×2), 2.07
(3H, s, 3-CH3), 2.36 (3H, s, 4-CH3), 2.83 (2H, s, 3’-CH2CO), 6.95 (1H, d, J = 8.8 Hz, 6-H),
7.91 (1H, d, J = 8.8 Hz, 5-H).
3,4-Dimethyl-4'-hydroxy-3',4'-dihydroseselin (10)
NaBH4 (11.4 g, 300 mmol) in water (50 mL) was dropped into a solution of 9 (27.2 g, 100
mmol) in MeOH (300 mL) at ice-bath temperature. Adding a few of drops of 1 M aq NaOH
kept the reaction in a basic condition. The mixture was stirred at room temperature for 12 h
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until the reaction was complete (TLC, petroleum/EtOAc 4:1). The pH was adjusted to 5–6 with
aq 5% HCl, and the mixture extracted with EtOAc three times. The organic phase was washed
with 5% NaHCO3, water, and brine successively. After drying over anhydrous Na2SO4, the
solvent was removed in vacuo to give crude 10 (25.5 g, 93% yield). The crude product could
be used in the next reaction without further purification. It was also purified by a flash silica
chromatography (eluant EtOAc/petroleum ether 0–30%) to give a light yellow solid, mp 166–
167 °C; 1H NMR δ 1.41 and 1.47 (each 3H, s, 2'-CH3), 2.13 (2H, d, J = 5.2 Hz, 3'-CH2), 2.19
(3H, s, 3-CH3), 2.38 (3H, s, 4-CH3), 3.23 (1H, s, 4'-OH), 5.26 (1H, m, 4'-H), 6.78 (1H, d, J =
9.2 Hz, 6-H), 7.45 (1H, d, J = 9.2 Hz, 5-H).
3,4-Dimethylseselin (11)
Compound 10 (27.4 g, 100 mmol) in anhydrous benzene (250 mL) in the presence of TsOH
(2 g, catalytic amount) was heated to reflux for 15 min with TLC monitoring (petroleum ether/
EtOAc 10:1). After cooling to room temperature, more EtOAc was added to the mixture, and
the organic phase was washed successively with 10% aq NaOH, water and brine, , and dried
over anhydrous Na2SO4, After removing solvent in vacuo, the residue was purified by a flash
column (silica, eluant: 0–10% EtOAc/petroleum ether) to give 25.0 g of 11, 98% yield,
colorless needle crystals from EtOH/H2O mp 135–136 °C (lit.121–122 °C); 1H NMR δ 1.47
(6H, s, 2'-CH3×2), 2.18 (3H, s, 3-CH3), 2.35 (3H, s, 4-CH3), 5.71 (1H, d, J = 9.6 Hz, 3'-H),
6.72 (1H, d, J = 8.8 Hz, 6-H), 6.91 (1H, d, J = 9.6 Hz, 4'-H), 7.35 (1H, d, J = 8.8 Hz, 5-H).
3,4-Dimethyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (12)
A mixture of K3Fe(CN)6 (20 g, 60 mmol), K2CO3 (10 g, 72.5 mmol), 2,5-diphenyl-4,6-bis(9-
Odihydroquinyl) pyrimidine [(DHQ)2-PYR] (531 mg, 0.6 mmol), and K2OsO2(OH)4 (220 mg,
0.6 mmol) was solubilized in 260 mL of t-BuOH/H2O (v/v, 1:1) at room temperature. Then,
the solution was cooled to 0 °C, and methanesulfonamide (1.9 g, 20 mmol) added under stirring.
When the solution turned from light yellow to orange, 11 (5.1 g, 20 mmol) was added. The
mixture was stirred at 0 °C for 24 h. Na2S2O5 (excess), water, and more CHCl3 were added.
After stirring for 0.5 h at room temperature, the mixture was extracted with CHCl3 three times.
The combined organic layer was dried over MgSO4, then solvent was removed in vacuo to
give 3,4-dimethyl-(+)-cis-khellactone, which was acylated directly, without further
purification, with (S)-(−)-camphanic chloride (13.0 g, 60 mmol) in pyridine/CH2Cl2 (100 mL
with 3:5 v/v) for 24 hours at room temperature monitored by TLC (cyclohexane/EtOAc 7:3).
The mixture was diluted with EtOAc and washed successively with 10% aq HCl, water and
brine. The organic phase was dried over anhydrous MgSO4, filtered, and concentrated in
vacuo. The residue was separated by a flash column eluting with a 0–50% gradiant of EtOAc/
hexane to give 5.0 g of pure 12 (77% yield), as calculated from 11, with 99.0 % stereoselectivity
for (3'R,4'R)-isomer measured by HPLC.
3-Bromomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (13)
A mixture of 12 (19.5 g, 30 mmol) and N-bromosuccinimide (NBS, 6.4 g, 36 mmol) in 50 mL
of anhydrous benzene was heated under reflux for 4 h until the reaction was completed as
monitored by TLC. The mixture was cooled at 4 °C overnight, the solid filtered, and the solvent
removed in vacuo to give a 19.7 g of 13 (97% yield), which was sufficiently pure to use in the
next reaction without further purification.
3-Cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (4)
A solution of sodium cyanide (0.69 g, 14 mmol) in 40 mL of 95% EtOH was cooled in an ice-
bath. Compound 13 (7.29 g, 10 mmol) in 15 mL of DMF was added slowly to the above solution
over a 15–20 min period. After 2 h of stirring at room temperature, the mixture was poured
into ice-water and extracted three times with EtOAc. The combined organic phase was washed
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with brine, dried (MgSO4), evaporated, and decolorized by passage through a short silica gel
column (cyclohexane/acetone/CH2Cl2 7:2:1) to afford the pure desired nitrile 4 (5.0 g, 74%);
white solid, mp 164–166 °C , d.e% 99.0 (measured by HPLC), [α]D +22.81° (c 1.01,
CHCl3); 1H NMR δ 1.08–1.12 (m.s. 18H, 6×CH3), 1.46 and 1.49 (each s, 3H, 2'-CH3), 1.66,
1.91, 2.18, and 2.51 (each m, 2×CH2), 2.52 (s, 3H, 4-CH3), 3.72 (s, 2H, 3-CH2), 5.40 (d, 1H,
J = 4.8 Hz, 3'-H), 6.65 (d, 1H, J = 4.8 Hz, 4'-H), 6.89 (d, 1H, J = 8.8 Hz, 6-ArH), 7.62 (d, 1H,
J = 8.8 Hz, 5-ArH); 13C NMR δ ppm 9.6 and 9.9 (2×CH3), 15.7 (3-CH2), 16.3, 16.4, 16.6, and
16.7 (4×CH3), 21.2 (2×CH3) and 26.1 (4-CH3), 28.9, 29.0, 30.9, and 31.3 (4×CH2), 54.6, 54.7,
54.9, and 55.1 (4×C), 61.5 and 72.1 (2×CH), 112.8 (CN), 90.7, 91.3, 106.3, 113.3, 116.3 (6×C),
114.9 and 127.2 (2×CH), 150.6, 152.2, 156.7, 159.2, 167.0, 167.4 (6×C), 177.4 and 178.6
(C=O); IR cm−1 (KBr): 2972, 2935; MS (ESI) m/z (%): 676.5 ([M+1]+, 100), 693.5 (M
+NH4 +,48), 698.5 (M+Na+,75). Anal. (C37H41O11N·) C 66.08, H 6.25, N 1.64, Calculated: C
65.77, H 6.12, N 2.07.
Isonitrile 4b
A mixture of 13 (73 mg, 0.1 mmol), Bu4N+I− (18.4 mg, 0.05 mmol), and sodium cyanide (11
mg, 0.22 mmol) in 10 mL of CH3CN was stirred at room temperature for 12 h. The mixture
was then poured into ice-water and extracted with EtOAc three times. The combined organic
phase was washed with brine, and dried over MgSO4. After removing the solvent in vacuo,
the residue was separated by PTLC (eluant: cyclohexane/acetone 2:1) to give 4b (36 mg, 53%
yield); 1H NMR δ 1.08–1.12 (m.s. 18H, 6×CH3), 1.46 and 1.50 (each s, 3H, 2'-CH3), 1.66,
1.91, 2.18, and 2.51 (each m, 2×CH2), 2.52 (s, 3H, 4-CH3), 5.27 (s, 2H, 3-CH2), 5.38 (d, 1H,
J = 4.8 Hz, 3'-H), 6.65 (d, 1H, J = 4.8 Hz, 4'-H), 6.88 (d, 1H, J = 8.8 Hz, 6-ArH), 7.63 (d, 1H,
J = 8.8 Hz, 5-ArH), 13C NMR δ ppm 9.55 and 9.63 (2×CH3), 15.26, 16.26, 16.36, 16.60, 16.66,
and 21.14 (6×CH3) and 26.13 (4-CH3), 28.91, 28.96, 29.20, and 30.55 (4×CH2), 54.20, 54.60,
and 54.89, 55.04. (4×C), 59.74 (3-CH2), 61.41, and 72.06 (2×CH), 90.72 (NC), 91.07, 91.30,
106.06, 113.44, 116.39 (5×C), 114.59 and 127.64 (2×CH), 152.35, 152.70, 156.62, 159.35,
166.89, 167.25 (6×C), 177.95, 178.01 and 178.51 (C=O); IR cm−1 (KBr): 2341, 2360 (NC);
MS (ESI) m/z (%): 676.5 ([M+1]+, 5), 649.5 (M-NC,10).
Detection of HIV-1 replication as measured by p24 antigen production
MT-2 and MT-4 cells, laboratory-adapted HIV-1 strains and primary HIV-1 isolates were
obtained from the NIH AIDS Research and Reference Reagent Program. The inhibitory activity
of compounds on HIV-1 infection was determined as previously described.24 In brief, 1 ×
104 MT-2 cells were infected with an HIV-1 strain (100 TCID50) in 200 µL RPMI 1640 medium
containing 10% FBS in the presence or absence of a test compound at graded concentrations
overnight. Then, the culture supernatants were removed and fresh media containing no test
compounds were added. On the fourth day post-infection, 100 µL of culture supernatants were
collected from each well, mixed with equal volumes of 5% Triton X-100 and assayed for p24
antigen, which was quantitated by ELISA. Briefly, wells of polystyrene plates (Immulon 1B,
Dynex Technology, Chantilly, VA) were coated with HIV immunoglobulin (HIVIG), which
was prepared from plasma of HIV-seropositive donors with high neutralizing titers against
HIV-1IIIB, in 0.085 M carbonate-bicarbonate buffer (pH 9.6) at 4 °C overnight, followed by
washes with washing buffer (0.01M PBS containing 0.05% Tween-20) and blocking with PBS
containing 1% dry fat-free milk (Bio-Rad Inc., Hercules, CA). Virus lysates were added to the
wells and incubated at 37 °C for 1 h. After extensive washes, anti-p24 mAb (183-12H-5C),
biotin labeled anti-mouse IgG1 (Santa Cruz Biotech., Santa Cruz, CA), streptavidin-labeled
horseradish peroxidase (Zymed, S. San Francisco, CA), and the substrate 3,3',5,5'-
tetramethylbenzidine (Sigma Chemical Co., St. Louis, MO) were added sequentially.
Reactions were terminated by addition of 1N H2SO4. Absorbance at 450 nm was recorded in
an ELISA reader (Ultra 386, TECAN, Research Triangle Park, NC). Recombinant protein p24
purchased from US Biological (Swampscott, MA) was included for establishing standard dose
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response curves. Each sample was tested in triplicate. The percentage of inhibition of p24
production was calculated as previously described.25 The effective concentrations for 50%
inhibition (EC50) were calculated using a computer program, designated CalcuSyn26, kindly
provided by Dr. T. C. Chou (Sloan-Kettering Cancer Center, New York, New York).
Inhibitory activity of compound 4 against infection of PBMCs by a primary HIV-1 isolate was
determined as previously described.27 Briefly, PBMCs were isolated from the blood of healthy
donors at the New York Blood Center by standard density gradient centrifugation using
Histopaque-1077 (Sigma). The cells were cultured in 75 cm2 plastic flasks at 37 °C for 2 h.
The non-adherent cells were collected and resuspended at 5 × 106 cells in 10 mL of RPMI-1640
medium containing 10% fetal bovine serum (FBS), 5 µg/mL phytohemagglutinin (PHA) and
100 U/mL IL-2 (Sigma), followed by incubation at 37 °C for 3 days. The PHA-stimulated cells
were infected with a primary HIV-1 isolate at a 0.01 multiplicity of infection (MOI) in the
presence or absence of the test compound at graded concentrations. Culture media were
changed on the second day and then every three days. The supernatants were collected seven
days post-infection and tested for p24 antigen by ELISA as described above. The percent
inhibition of p24 production and EC50 values were calculated as described above.
Assessment of in vitro cytotoxicity
The in vitro cytotoxicity of compounds on MT-2 cells was measured by XTT assay.15 Briefly,
100 µL of the test compound at graded concentrations were added to equal volumes of cells
(5 × 105/mL) in wells of 96-well plates. After incubation at 37 °C for 4 days, 50 µL of XTT
solution (1 mg/mL) containing 0.02 µM of phenazine methosulphate (PMS) was added. After
4 h, the absorbance at 450 nm was measured with an ELISA reader. The CC50 (concentration
for 50% cytotoxicity) values were calculated using a computer program, CalcuSyn.28
Pharmacokinetic assessments
Chromatographic analyses were performed using a Gold ODS-C18 column (3 µm, 150 × 2.1
mm, Hypersil™ Thermo USA) kept at 20 °C, the mobile phase composed of acetonitrile–
water–formic acid in the ratio of 65:35:0.1 (v/v/v) at a flow rate of 0.2 mL/min. Acetonitrile
was HPLC grade and other chemical reagents and solvents were of analytical grade. A Thermo
Finnigan TSQ tandem mass spectrometer equipped with ESI source (San Jose, CA, USA) and
Surveyor LC pump were used for LC–MS/MS analysis. Data acquisition and data processing
were performed by using Xcalibur software and LCQuan 2.0 data analysis program (Thermo
Finnigan), respectively. Optimized MS parameters were as below: 4500 v spray voltage, 12.6
psi sheath gas pressure, 3.3 psi auxiliary valve flow, and 280 °C of capillary temperature. The
selected reaction monitoring (SRM) mode was used and transitions selected for quantification
were as follows: m/z 698.0→m/z 292.8 for test compounds and m/z 285.1→m/z 138.0 for
internal standard (IS) synthesized by pharmaceutical laboratory. Optimized collision energy
of 47 eV was used for test compounds and 21 eV for IS. Scan time was 0.5 s per transition.
Solutions of test compounds and IS were infused into the mass spectrometer.
Preparation of samples
Using a simple protein precipitation method, a test compound was extracted from rat plasma.
Plasma samples for standard curves were prepared by spiking 100 µL of rat plasma with 50
µL various concentrations of each test compound ranging from 10 to 10000 ng/mL and a
constant volume (50 µL) of the internal standard (IS) (2 µg/mL in acetonitrile). The final
concentrations of standards were set to 5, 10, 50, 100, 200, 1000, 2000, and 5000 ng/mL. To
each tested plasma sample (100 µL), 50 µL of the same concentration of IS was added. The
plasma was then mixed with 400 µL of acetonitrile. After vortexing and centrifugation at
10,000 g for 10 min, the supernatant was transferred to autosampler vials, and only 5 µL of
the supernatant was injected into the LC-MS/MS system for analysis. The calibration curve y
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= ax + b was obtained by assigning the concentration of T and the peak area ratio of T to I.S.
and to x and y, respectively. Subsequently, a 1/x weighted linear regression was performed.
The amount of each test compound in the plasma samples was back-calculated using the
standard curves.
In vivo animal test
Three male Sprague–Dawley rats were used in each study. Each of these rats was dosed with
a testing compound at 20 mg/kg for i.g. administration and 2 mg/kg for i.v. administration each
in CMC. Blood samples were collected at 0, 5, 10, 30, 60, 120, 180, 240, 300 and 360 min
(Figure 2) and were immediately centrifuged to separate the plasma fractions. When compound
4 was administrated in 10% PEG400, the blood samples were collected at 0, 5, 15, 30, 60, 120,
180, 300, 480, and 720 min (Figure 3). The plasma samples obtained were stored at −20 °C
until analysis. Concentration-versus-time profiles were obtained for each analyte, and standard
non-compartmental analysis was performed on the data using DAS Version 2.0 to recover the
area under the curve (AUC) and other non-compartmental parameters. Bioavailability was
estimated by dividing the dose-normalized AUC (0 - t) resulting from oral administration by
the AUC (0 - t) resulting from intravenous administration (where t is the last time point with
measurable drug concentrations in the study). Data for each pharmacokinetic parameter were
averaged and reported as mean ± standard deviation. Calibration curves for testing compounds
in plasma were linear in the concentration range of 5–5000 ng/mL, with correlation coefficients
≥ 0.990 for all curves.
Caco-2 cell experiment
Caco-2 monolayers exhibiting a transepithelial electrical resistance (TEER) value of more than
300 Ωcm2 were used within 21 days post-seeding. The culture medium was removed from
both apical (AP) and basolateral (BL) sides and the monolayers were washed twice with warm
phosphate buffered saline (PBS) with calcium and magnesium. The monolayers were pre-
incubated at 37 °C for 30 min in a CO2 incubator with pre-warmed transport media. The
transport medium consisted of Hanks Balanced Salt solution (HBSS), 10 mM HEPES buffer,
25 mM D-glucose, and the pH was adjusted to 7.4. Testing compounds at final concentrations
of 10 mM in HBSS were added to the apical compartment. The basolateral compartment
contained only HBSS. All transport studies were conducted in the AP to BL direction. At
selected times, ranging from 10 to 60 min, 50 µL of samples were removed from the BL
compartment for analysis and replaced with an equal volume of HBSS. Samples were analyzed
using liquid chromatography mass spectrometry (LC/MS). The initial flux of the drug (J) was
determined from the slope of the linear plot of the cumulative amount of drug transported
versus time. Permeability was estimated by calculating the apparent permeability coefficient
(Papp)29 according to: Papp = J/ASC0, in which C0 is the initial concentration in the donor
compartment and AS is the surface area of the monolayer.
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Structures of DCK analogs
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Mean plasma concentration-versus-time curves of 3 and 4 with CMC after i.v. administration
at 2 mg/kg (above) and i.g. administration at 20 mg/kg (bottom) to SD rats (n = 3) respectively.
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Mean plasma concentration-versus-time curves of 4 in PEG400 after i.v. administration at 2
mg/kg (left) and i.g. administration at 20 mg/kg (right) to SD rats (n = 3), respectively.s
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Scheme 1. Synthesis of compound 4
(i) ethyl 2-methylacetoacetate/H2SO4; (a) 3-chloro-3-methyl-1-butyne/DMF/K2CO3/KI; (b)
reflux in N,N-diethylaniline; (ii) Ac2O; (iii) AlCl3, high temperature; (iv) acetone/pyrrolidine;
(v) NaBH4/MeOH; (vi) TsOH/benzene, reflux; (vii) K3Fe(CN)6, K2CO3, (DHQ)2-PYR,
K2Os2(OH)4, t-BuOH/H2O (v/v=1:1), 0 °C; (viii) (S)-camphanic chloride, CH2Cl2/Py; (ix)
NBS/benzene, reflux; (x) NaCN, see Table 2 for reaction conditions and products.
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Table 1
Yields in original and new synthetic routes for target compound 4
Steps Improved yield (%) Original yield (%)3,6
5→6 97 87
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Table 3
Spectroscopic data differences between nitrile (4) and isonitrile (4b)
Spectra Nitrile (4) Isonitrile (4b)
1H NMR (δppm) 3.72 3-CH2CN 5.27 3-CH2NC
13C NMR (δppm) 15.7 3-CH2CN 59.5 3-CH2NC
IR cm−1 2972 2935 2341 2360 (NC)
MS (ESI) m/z (%) 676.5 ([M+1]+, 100) 676.5 ([M+1]+, 5), 649.(M−NC,10)
HPLC a (Rt) 10.9 min 5.6 min
a
HPLC: column: C18 Axxion, 15 cm × 0.4, mobile phase: 60% acetonitrile plus 25 mM HOAc/H2O, 1.5 mL/min, λ= 320 nm.
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Table 4
Anti-HIV activity comparison of DCK analog candidates 2, 3, and 4 in H9 lymphocytes in previous publications.*4,6
DCK analog IC50 (µM) EC50 (µM) TI
2 23.6 0.0015 4 15,733
3 24.9 0.004 4 6,225
4 >37.0 0.0024 6 15,417
*
Data presented are averages of at least two separate experiments performed by Panacos Pharmaceuticals Inc.
IC50 Concentration that inhibits uninfected H9 cell growth by 50%. EC50Concentration that inhibits viral replication by 50%. TI= IC50 / EC50. Assay
method see reference.4,6
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Table 6
Inhibitory activity of 4 against HIV-1 RT resistant strains in MT-2 cell line
EC50 (µM)
Multi-RT resistant HIV-1 strains 4 Nevirapine
8605MR 1.81 (8.96-fold)* >14.80 (>51.21-fold)*
6005MR 0.43 (2.13-fold)* >14.80 (>51.21-fold)*
7324-1 3.93 (14.41-fold)* >14.80 (>51.21-fold)*
Wild type -HIV-1IIIB 0.20 0.29
8605MR: 41L, 67N, 210W, 215Y, 184V, 103N
6005MR: 41L,74V, 184V, 210W, 215Y, ins SS, 98G
7324-1: multidrug resistant HIV-1 reverse transcriptase (RT) clone.
*
Compared with EC50 of wild-type virus
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Table 7
Antiviral activity of 4 against infection of PBMCs by primary HIV-1 isolates of distinct subtypes and tropisms
Isolates Subtype Tropism EC50 (µM)
* EC90 (µM)
94UG103 A X4R5 0.84 ± 0.07 1.63 ± 0.30
92US657 B R5 5.09 ± 0.58 9.22 ± 1.02
93MW959 C R5 0.87 ± 0.079 3.06 ± 0.68
92UG001 D X4R5 0.98 ± 0.35 5.23 ± 2.44
93BR020 F X4R5 2.18 ± 0.04 3.76 ± 0.13
RU570 G R5 3.27 ± 0.17 8.93 ± 0.19
BCF02 Group O R5 9.92 ± 1.15 18.1 ± 2.3
*
Tests were done in triplicate and the data presented as mean ± SD. The CC50 value of 4 to PBMCs is >150 µM.
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